Table 5.

Regression Analysis—Lost to Follow-Up Risk Among Children and Adolescents Initiating Antiretroviral Therapy in Central Kenya (2004–2014)

Outcome: LTFU	Univariable results		Multivariable results
Imputed models	sHR (95% CI)	p	sHR (95% CI)	p
Age groups, years
0–4	Ref.		Ref.
5–9	0.84 (0.75–0.95)	.007	0.93 (0.74–1.17)	.551
10–14	0.91 (0.84–0.98)	.015	1.05 (0.80–1.38)	.735
15–19	1.35 (1.19–1.54)	<.001	1.26 (1.00–1.59)	.051
Sex
Male	Ref.		Ref.
Female	1.25 (1.12–1.40)	<.001	1.16 (1.05–1.29)	.003
Regimen
D4T based	Ref.		Ref.
AZT based	1.03 (0.64–1.64)	.916	1.02 (0.65–1.59)	.933
TDF based	3.03 (1.43–6.42)	.004	2.37 (1.23–4.58)	.010
ABC based	1.66 (0.74–3.75)	.221	1.64 (0.74–3.66)	.225
Baseline WHO stage
Stage I	0.98 (0.65–1.46)	.902	0.92 (0.63–1.35)	.676
Stage II	1.16 (0.67–2.02)	.599	1.08 (0.71–1.63)	.722
Stage III	1.56 (0.75–3.25)	.237	1.35 (0.83–2.22)	.228
Stage IV	Ref.		Ref.
TB status
No signs	Ref.		Ref.
On TB treatment	1.22 (0.59–2.53)	.593	1.37 (0.69–2.75)	.372
Presumptive TB	2.30 (1.39–3.79)	.001	2.59 (1.78–3.77)	<.001

AZT, zidovudine; D4T, stavudine; WHO, World Health Organization; TX, treatment.